Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up.

  title={Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up.},
  author={Sylvie Houde and M. Filiatrault and A. Fournier and Julie Dub{\'e} and S. D’Arcy and D. B{\'e}rub{\'e} and Y. Brousseau and G. Lapierre and M. Vanasse},
  journal={Pediatric neurology},
  volume={38 3},
  • Sylvie Houde, M. Filiatrault, +6 authors M. Vanasse
  • Published 2008
  • Medicine
  • Pediatric neurology
  • Data reported here were collected over an 8-year period for 79 Duchenne muscular dystrophy patients, 37 of whom were treated with deflazacort. Mean length of treatment was 66 months. Treated boys stopped walking at 11.5 +/- 1.9 years, compared with 9.6 +/- 1.4 years for untreated boys. Cardiac function was better preserved with the use of deflazacort, as shown by a normal shortening fraction in treated (30.8 +/- 4.5%) vs untreated boys (26.6 +/- 5.7%, P < 0.05), a higher ejection fraction (52.9… CONTINUE READING
    Comparison of Deflazacort and Prednisone in Duchenne Muscular Dystrophy
    • 5
    • PDF
    Forty-Five Years of Duchenne Muscular Dystrophy in The Netherlands.
    • 3
    All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy.
    • 124


    Publications referenced by this paper.
    Deflazacort treatment of Duchenne muscular dystrophy.
    • 197
    • Highly Influential
    • PDF
    Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade
    • 306
    • Highly Influential
    • PDF
    Deflazacort in Duchenne dystrophy: Study of long‐term effect
    • 144
    Long‐Term Steroid Therapy in Duchenne Muscular Dystrophy–Positive Results versus Side Effects
    • 51
    • Highly Influential
    Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study
    • 62
    Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy.
    • 114